295 related articles for article (PubMed ID: 34289354)
1. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M; Barras D; Mina M; Ghisoni E; Morotti M; Lanitis E; Fahr N; Desbuisson M; Grimm A; Zhang H; Chong C; Dagher J; Chee S; Tsianou T; Dorier J; Stevenson BJ; Iseli C; Ronet C; Bobisse S; Genolet R; Walton J; Bassani-Sternberg M; Kandalaft LE; Ren B; McNeish I; Swisher E; Harari A; Delorenzi M; Ciriello G; Irving M; Rusakiewicz S; Foukas PG; Martinon F; Dangaj Laniti D; Coukos G
Cell Rep; 2021 Jul; 36(3):109412. PubMed ID: 34289354
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
[TBL] [Abstract][Full Text] [Related]
3. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
[TBL] [Abstract][Full Text] [Related]
5. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
7. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
[TBL] [Abstract][Full Text] [Related]
8. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
McLaughlin LJ; Stojanovic L; Kogan AA; Rutherford JL; Choi EY; Yen RC; Xia L; Zou Y; Lapidus RG; Baylin SB; Topper MJ; Rassool FV
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17785-17795. PubMed ID: 32651270
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
[TBL] [Abstract][Full Text] [Related]
12. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
Wang Q; Bergholz JS; Ding L; Lin Z; Kabraji SK; Hughes ME; He X; Xie S; Jiang T; Wang W; Zoeller JJ; Kim HJ; Roberts TM; Konstantinopoulos PA; Matulonis UA; Dillon DA; Winer EP; Lin NU; Zhao JJ
Nat Commun; 2022 May; 13(1):3022. PubMed ID: 35641483
[TBL] [Abstract][Full Text] [Related]
13. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
15. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
[TBL] [Abstract][Full Text] [Related]
16. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
17. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
[TBL] [Abstract][Full Text] [Related]
20. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
